Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
The scope of a well-known mark: not always as broad as some might wish The scope of a well-known mark: not always as broad as some might wish Reviewed by Neil Wilkof on Tuesday, March 14, 2017 Rating: 5
Never Too Late: If you missed the IPKat last week! Never Too Late: If you missed the IPKat last week! Reviewed by Tian Lu on Monday, March 13, 2017 Rating: 5

Monday miscellany

1.  Voices --  "EU Copyright Reform Proposals Unfit for the Digital Age." "While the Proposed Directive on Copyright in ...
- Monday, March 13, 2017
Monday miscellany Monday miscellany Reviewed by Tian Lu on Monday, March 13, 2017 Rating: 5

Around the IP Blogs

MARQUES Class 46 (trade marks)   * EUIPO “smart-seals” (?) equality The 5th Board of Appeal’s decision (Case R 1488/2016-5) on the r...
- Monday, March 13, 2017
Around the IP Blogs Around the IP Blogs Reviewed by Tian Lu on Monday, March 13, 2017 Rating: 5
UK's IP Enforcement Framework-IPO Research Bid Opportunity (Update) UK's IP Enforcement Framework-IPO Research Bid Opportunity (Update) Reviewed by Neil Wilkof on Monday, March 13, 2017 Rating: 5
Shall we dance? Regulatory approval, trade secrets and the transatlantic biosimilars patent wars Shall we dance? Regulatory approval, trade secrets and the transatlantic biosimilars patent wars Reviewed by Annsley Merelle Ward on Sunday, March 12, 2017 Rating: 5
Biosimilars and generics as "rip-offs": when the facts may not matter Biosimilars and generics as "rip-offs": when the facts may not matter Reviewed by Neil Wilkof on Friday, March 10, 2017 Rating: 5
UK's IP Enforcement Framework - IPO Research Bid Opportunity UK's IP Enforcement Framework - IPO Research Bid Opportunity Reviewed by Hayleigh Bosher on Friday, March 10, 2017 Rating: 5
Curtain - Merpel's final EPO post Curtain - Merpel's final EPO post Reviewed by Merpel on Friday, March 10, 2017 Rating: 5
Amgen, Pfizer, Alphabet and Uber face up to trade secrets in biosimilars, self driving cars and product launch plans Amgen, Pfizer, Alphabet and Uber face up to trade secrets in biosimilars, self driving cars and product launch plans Reviewed by Annsley Merelle Ward on Thursday, March 09, 2017 Rating: 5
Subscribe to: Comments ( Atom )
Powered by Blogger.